ABSTRACT
Background Respiratory syncytial virus can cause severe disease in the older adult population. Three vaccines for RSV are currently market approved but the risk of RSV-hospitalization in (older) adults from a community level remains elusive. We aimed to estimate the risk of RSV-hospitalization and characterize the patients that end up in hospital.
Methods We retrospectively analyzed records of adults aged ≥20 with RSV-infection between 2022-2024 in three hospitals in the Netherlands. These hospitals implemented routine RSV-testing using the GeneXpert CoV-2/Flu/RSV at Emergency Departments. Using population-based data in combination with the in-hospital data, we estimated the population risk of RSV-hospitalization. Additionally, hospital records were analyzed to characterize RSV-patients and their course of disease.
Results We investigated 709 RSV cases of whom 503 (70.9%) were hospitalized. 526 patients were ≥60, and 183 were <60 years of age. The population risk of RSV-hospitalization ranged from 0.006-0.02% for patients aged 20-59 years and 0.04-0.24% for those ≥60. The highest risks were seen in older patients with congestive heart disease (0.14-5.0%) and COPD (0.17-1.76%). RSV caused clinically relevant infection in 88% of hospital visits. Underlying comorbidity was prevalent (88.5%) and exacerbation of underlying disease by RSV caused of 46.3% of RSV-related hospital admissions. ICU admittance was 11.2% and in-hospital mortality was 8.1%.
Conclusion Generally, the risk of RSV-hospitalization from the community is low. Older age, but mainly comorbidities increased this risk. Exacerbation of underlying disease was the main reason for RSV-related hospitalization. This indicates that RSV vaccines should primarily target those with high risk comorbidities.
TAKE HOME MESSAGE Generally, the risk of RSV-hospitalization from the community is low as observed in our study. Older age, but mainly comorbidities increased this risk. This indicates that RSV vaccines should primarily target those with high risk comorbidities.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work. KK; No personal fees received. The Amsterdam UMC has received funding for participation in the following activities; educational activities (Expert speaker in Webinar, MedTalks; Webinar, PRIME education; RSV Podcast, Pfizer; and creation of an e-learning module, Farmacotherapie-online), participation on an advisory board from Pfizer. No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the Medical Ethics Committee Brabant (reference number NW2024-23) and individual patient informed consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
